“十四五”创新药“成绩单”：210个获批，多项指标均位居世界前列

Group 1 - The core point of the article highlights that from January to July this year, the National Medical Products Administration (NMPA) has approved 50 innovative drugs, surpassing the total of 48 approved in the entire previous year, indicating a strong growth trend in drug approvals [1][5] - During the "14th Five-Year Plan" period, the NMPA has approved a total of 210 innovative drugs, maintaining an accelerated growth trajectory [1] - China ranks among the top globally in terms of the number of innovative drug pipelines and clinical trial projects, reflecting a robust momentum in pharmaceutical innovation [1][7] Group 2 - Among the 50 newly approved drugs this year, several high-profile products have gained significant public attention, including the country's first stem cell therapy drug and treatments for rare diseases [3] - The NMPA's Director of Drug Registration Management, Yang Ting, noted that many of the approved drugs target major diseases such as cancer, metabolic disorders, and immune diseases, including the first gene therapy product for Hemophilia B [5] - The shift in drug development focus from similar and improved drugs to original innovations is attributed to the NMPA's policies aimed at clinical value, with China currently holding about one-quarter of the global innovative drug development pipeline [7]